Login to Your Account



IL-1 Trap Phase II Trial Misses; Regeneron Still Behind Drug

By Kim Coghill


Wednesday, October 8, 2003
Despite Wall Street's not-so-positive view of data from Regeneron Pharmaceuticals Inc.'s Phase II trial of its interleukin-1 Trap product in rheumatoid arthritis, the company believes the 200-patient trial demonstrates enough biological effect to forge ahead. (BioWorld Today)

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription